Our data suggest that EGFR inhibitor–based therapy combined with deguelin showed a better benefit for HNSCC patients with the PIK3CA mutation, which are often resistant to EGFR TKI monotherapy. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.